Abstract
Inhibition of thrombin receptor (PAR-1) is a promising therapeutic approach for the treatment of various cardiovascular disorders such as unstable angina, acute myocardial infarction, stroke, and restenosis. Since a PAR- 1 antagonist is specific for the cellulalr actions of thrombin, and does not interfere with fibrin generation, it is expected to have less bleeding liability than the currently available treatments. Several peptide and non-peptide PAR-1 antagonists with potent inhibition of platelet aggregation have been reported. Antithrombotic effect of a PAR-1 antibody has been demonstrated in a baboon thrombosis model and the antirestenosis property of a PAR-1 antagonist has been demonstrated in a rat model.
Keywords: G-Protein, thrombin receptor, acute myocardial infarction, baboon thrombosis model, restenosis
Current Topics in Medicinal Chemistry
Title: G-Protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents (Hot Topic: Structure and property Approaches in Recent Drug Discovery Guest Editor: Guo Zhu Zheng)
Volume: 3 Issue: 10
Author(s): Samuel Chackalamannil
Affiliation:
Keywords: G-Protein, thrombin receptor, acute myocardial infarction, baboon thrombosis model, restenosis
Abstract: Inhibition of thrombin receptor (PAR-1) is a promising therapeutic approach for the treatment of various cardiovascular disorders such as unstable angina, acute myocardial infarction, stroke, and restenosis. Since a PAR- 1 antagonist is specific for the cellulalr actions of thrombin, and does not interfere with fibrin generation, it is expected to have less bleeding liability than the currently available treatments. Several peptide and non-peptide PAR-1 antagonists with potent inhibition of platelet aggregation have been reported. Antithrombotic effect of a PAR-1 antibody has been demonstrated in a baboon thrombosis model and the antirestenosis property of a PAR-1 antagonist has been demonstrated in a rat model.
Export Options
About this article
Cite this article as:
Chackalamannil Samuel, G-Protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents (Hot Topic: Structure and property Approaches in Recent Drug Discovery Guest Editor: Guo Zhu Zheng), Current Topics in Medicinal Chemistry 2003; 3 (10) . https://dx.doi.org/10.2174/1568026033452122
DOI https://dx.doi.org/10.2174/1568026033452122 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Biochemical Markers in Acute Coronary Syndromes
Current Medicinal Chemistry Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Potential Mechanisms and Clinical Effectiveness of Acupuncture in Depression
Current Neuropharmacology True or False? Activations of Language-related Areas in Patients with Disorders of Consciousness
Current Pharmaceutical Design Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Pentraxin Level is the Key to Determine Primary Percutaneous Coronary Intervention (PCI) or Fibrinolysis
Cardiovascular & Hematological Disorders-Drug Targets Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
CNS & Neurological Disorders - Drug Targets RAS Inhibition Attenuates Cognitive Impairment by Reducing Blood- Brain Barrier Permeability in Hypertensive Subjects
Current Hypertension Reviews Editorial from Editor-in-Chief [‘Chronic Obstructive Pulmonary Disease: Economical Burden and Quality of Life in 2008”]
Current Respiratory Medicine Reviews Association of Non-Traditional Lipid Parameters with Hemorrhagic Transformation and Clinical Outcome After Thrombolysis in Ischemic Stroke Patients
Current Neurovascular Research Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Acknowledgements to Reviewers
Current Hypertension Reviews Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Olive Oil-related Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
Current Vascular Pharmacology Imaging of Neurotrauma in Acute and Chronic Settings
Current Neuropharmacology Chelating Systems for 99mTc/188Re in the Development of Radiolabeled Peptide Pharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke
Current Pharmaceutical Design